Estrogen therapy in gynecological cancer survivors

References

• Trinh X-B, Peeters F, Tjalma WAA. The thoughts of breast cancer survivors regarding the need for starting hormone therapy. Eur J Obstset Gynecol Rep Biol 2006;124:250–3
   PubMed Web of Science ®Google Scholar
• Hinds L, Price J. Menopause, hormone replacement and gynaecologic cancers. Menopause Int 2010;16:89–93
   PubMedGoogle Scholar
• Green D, Sklar C, Boice J, Mulvihill J, Stovall M. Ovarian failure and reproductive outcomes after childhood cancer treatment: results from the Childhood Cancer Survivor Study. J Clin Oncol 2009:34:2374–81
   Web of Science ®Google Scholar
• Sklar C. Maintenance of ovarian function and risk of premature menopause related to cancer treatment. J Natl Cancer Inst Monogr 2005;27:25–7
   Google Scholar
• Bath LE, Critchley OD, Chambers SE, Anderson RA, Kelmar JH, Wallace WHB. Ovarian and uterine characteristics after total body irradiation in childhood and adolescence: response to sex steroid replacement. BJOG 1999;106:1265–72
   Web of Science ®Google Scholar
• Wallace WH, Thomson AB, Kelsey TW. The radiosensitivity of the human oocyte. Hum Reprod 2003;18:117–21
   PubMed Web of Science ®Google Scholar
• Creasman W. Hormone replacement therapy after cancer. Curr Opin Oncol 2005;17:493–9
   PubMed Web of Science ®Google Scholar
• Committee on Gynecologic Practice: ACOG committee opinion. Hormone replacement therapy in women treated for endometrial cancer: Number 234, May 2000. Int J Gynecol Obstet 2001;73: 283–4
   PubMed Web of Science ®Google Scholar
• Hershlag A, Schuster M. Return of fertility after autologous stem cell transplantation. Fertil Steril 2002;77:419–23
   PubMed Web of Science ®Google Scholar
• Gallup DG, Stock RJ. Adenocarcinoma of the endometrium in women 40 years or younger. Obstet Gynecol 1984;64:417–20
   PubMed Web of Science ®Google Scholar
• DiSaia PJ, Creasman WT, eds. Adenocarcinoma of the uterus. In Clinical Gynaecologic Oncology, 6th edn. Philadelphia: Mosby, 2002:137–71
   Google Scholar
• Creasman WT, Henderson D, Hinshaw W, Clarke-Pearson DL. Estrogen replacement therapy in the patient treated for endometrial cancer. Obstet Gynecol 1986;67:326–30
   PubMed Web of Science ®Google Scholar
• Lee RB, Burke TW, Park RC. Estrogen replacement therapy following treatment for stage 1 endometrial carcinoma. Gynecol Oncol 1990;36:189–91
   PubMed Web of Science ®Google Scholar
• Bryant CW. Administration of estrogens to patients with a previous diagnosis of endometrial adenocarcinoma. South Med J 1990;83:725–6
   PubMed Web of Science ®Google Scholar
• Baker DD. Estrogen replacement therapy in patients with previous endometrial carcinoma. Compre Ther 1990;16:28–35
   PubMedGoogle Scholar
• Chapman JA, DiSaia PJ, Osann K. Estrogen replacement in surgical stage I and II endometrial cancer survivors. Am J Obstet Gynecol 1996;175:1195–200
   PubMed Web of Science ®Google Scholar
• Suriano KA, Mchale M, Mclaren CE, Kuo-Tung Li, Re A, Disaia PJ. Estrogen replacement therapy in endometrial cancer patients: a matched control study. Obstet Gynecol 2001;97:555–60
   PubMed Web of Science ®Google Scholar
• Barakat RR, Bundy BN, Spirtos NM, Bell J, Manuel RS. Randomised double-blind trial of estrogen replacement therapy versus placebo in stage I or II endometrial cancer: a gynaecologic oncology group study. J Clin Oncol 2006; 24:587–92
   PubMed Web of Science ®Google Scholar
• Ayhan A, Taskiran C, Simsek S, Sever A. Does immediate hormone therapy affect the oncologic outcome in endometrial cancer survivors?Int J Gynaecol Cancer 2006;16:805–8
   Web of Science ®Google Scholar
• Thanopoulou E, Judson I. Hormonal therapy in gynaecological sarcomas. Exp Rev Anticancer Ther 2012;12:885–94
   PubMed Web of Science ®Google Scholar
• Hinds L, Price J. Menopause, hormone replacement and gynaecological cancers. Menopause Int 2010;16:89–93
   PubMedGoogle Scholar
• MacLennan AH. HRT in difficult circumstances: are there any absolute contraindications?. Climacteric 2011;14:409–17
   PubMed Web of Science ®Google Scholar
• Chu MC, Mor G, Lim C, Zheng W, Parkash, Schwartz PE. Low grade endometrial stromal sarcoma: hormonal aspects. Gynecol Oncol 2003;90:170–6
   PubMed Web of Science ®Google Scholar
• Simon J, Nachtigall I, Ulrich LG, Eugster-Hausmann M, Gut R. Endometrial safety of ultra-low-dose estradiol vaginal tablets. Obstet Gynecol 2010;116:876–83
   PubMed Web of Science ®Google Scholar
• Guidozzi F, Ball J. Extensive primary cytoreductive surgery for advanced epithelial cancer. Gynecol Oncol 1994;53:326–30
   PubMed Web of Science ®Google Scholar
• Guidozzi F. Living with ovarian cancer. Gynecol Oncol 1993;50:202–7
   PubMed Web of Science ®Google Scholar
• Eeles RA, Tan S, Wiltshaw E, et al. Hormone replacement therapy and survival after surgery for ovarian cancer. BMJ 1991; 302:259–62
   PubMed Web of Science ®Google Scholar
• Guidozzi F, DaPonte A. Estrogen replacement therapy for ovarian carcinoma survivors. A randomized controlled study. Cancer 1999;86:1013–18
   PubMed Web of Science ®Google Scholar
• Bebar S, Ursic-Vrscaj M. Hormone therapy after epithelial cancer. Eur J Gynaecol Oncol 2000;21:192–6
   PubMed Web of Science ®Google Scholar
• Ursic-Vrscaj M. Hormone replacement therapy after invasive ovarian serous cystadencarcinoma treatment: the effect on survival. Menopause 2001;8:1460–5
   Web of Science ®Google Scholar
• Mascarenhas C, Lambe M, Bellocco R, et al. Use of hormone replacement therapy before and after ovarian cancer diagnosis and ovarian survival. Int J Cancer 2006;119:2907–15
   PubMed Web of Science ®Google Scholar
• International Agency for Research on Cancer, World Health Organization. GLOBCAN 2008. http://globcan.iarc.fr/
   Google Scholar
• WHO/ICO Information Centre on Human Papilloma Virus (HPV) and cervical cancer. http://who.int/hpvcentre
   Google Scholar
• Denny L. Cervical cancer prevention: New opportunities for primary and secondary prevention in the 21st century. Int J Gynecol Obstet 2012;119:S80–4
   Web of Science ®Google Scholar
• Parazzini F, Vecchia C, Negri E. Case control study of oestrogen replacement therapy and risk of cervical cancer. BMJ 1997;315: 85–8
   PubMed Web of Science ®Google Scholar
• Ferenczy A, Gelfand MM, Franco E, Mansour N. Human papillomavirus infection in postmenopausal women with and without hormone therapy. Obstet Gynecol 1997;90:7–11
   PubMed Web of Science ®Google Scholar
• Brand AH, Bull CA, Cakir B. Vaginal stenosis in patients treated with radiotherapy for carcinoma of the cervix. Int J Gynecol Cancer 2006;16:288–93
   PubMed Web of Science ®Google Scholar
• Sturdee DW, Panay N, International Menopause Society Writing Group. Recommendations for the management of postmenopausal vaginal atrophy. Climacteric 2010;13:509–22.
   PubMed Web of Science ®Google Scholar
• Ploch E. Hormonal replacement therapy in patients after cervical cancer treatment. Gynecol Oncol 1987;26:169–77
   PubMed Web of Science ®Google Scholar
• Lacey JV, Brinton LA, Barnes WA. Use of hormone replacement therapy and adenocarcinoma and squamous cell carcinomas of the cervix. Gynecol Oncol200;77:149–54
   Google Scholar
• MacKie RM, Bray CA. Hormone replacement therapy after surgery for stage 1 or 2 cutaneous melanoma. Br J Cancer 2004;90: 770–2
   PubMed Web of Science ®Google Scholar
• Madsen BS, Jensen HL, Van den Brule AJ, Wohlfahrt J, Frisch M. Risk factors for invasive squamous cell carcinoma of the vulva and vagina – population-based case-control study in Denmark. Int J Cancer 2008;122:2827–34
   PubMed Web of Science ®Google Scholar
• Hancke K, Foeldi M, Zahradnik HP, Gitsch G, Gilbert L, Denschlag D. Estrogen replacement therapy after endometrial cancer: a survey of physician's prescribing practice. Climacteric 2010;13:271–7
   PubMed Web of Science ®Google Scholar
• Vavillis D, Chatzigeorgiou K, Goulis D, et al. Hormonal replacement therapy in ovarian cancer survivors: a survey among Greek gynaecologists. Eur J Gynaecol Oncol 2011;32:538–41
   PubMed Web of Science ®Google Scholar
• Vavillis D, Tsolakidis D, Goulis DG, et al. Hormone therapy for postmenopausal endometrial cancer survivors: a survey among Greek obstetricians-gynaecologists. Eur J Gynaecol Oncol 2011;32: 81–3
   PubMed Web of Science ®Google Scholar
• Burger CW, van Leeuwen FE, Scheele F, Kenemans P. Hormone replacement therapy in women treated for gynaecological malignancy. Maturitas 1999;32:69–76
   PubMed Web of Science ®Google Scholar
• Lin K, Runowicz CD. The wisdom of hormone replacement therapy in survivors of ovarian and endometrial cancer. Gynecol Oncol 2001;81:987–93
   Web of Science ®Google Scholar
• Biglia N, Gadduci A, Ponzone R, Roagna R, Sismondi P. Hormone therapy in cancer survivors. Maturitas 2004;48:333–46
   PubMed Web of Science ®Google Scholar
• Michaelson-Cohen R, Beller U. Managing menopausal symptoms after gynaecological cancer. Curr Opin Oncol 2009;21:407–11
   PubMed Web of Science ®Google Scholar
• Hinds L, Price J. Menopause, hormone replacement and gynaecological cancers. Menopause Int 2010;16:89–93
   PubMedGoogle Scholar
• Singh P, Oehler MK. Hormone replacement after gynaecological cancer. Maturitas 2010;65:190–7
   PubMed Web of Science ®Google Scholar
• Ibeanu O, Modesitt SC, Ducie J, von Gruenigen V, Agueh M, Fader AF. Hormone replacement therapy in gynaecologic cancer survivors: why not?Gynecol Oncol 2011;122:447–54
   PubMed Web of Science ®Google Scholar
• Manley K, Edey K, Braybrooke J, Murdoch J. Hormone replacement therapy after endometrial cancer. Menopause Int 2012;18:134–8
   PubMedGoogle Scholar
• Biliatis I, Thomakos N, Rodolakis A, Akrivos N, Zacharakis D, Antsaklis A. Safety of hormone replacement therapy in gynaecological cancer survivors. J Obstet Gynaecol 2012;32:321–5
   PubMedGoogle Scholar
• Cairu L, Samsioe G, Iosif C. Quality of life in endometrial cancer survivors. Maturitas 1999;31:227–36
   PubMed Web of Science ®Google Scholar